Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


Articles published in J Virol

Retrieve available abstracts of 127 articles:
HTML format
Text format



Single Articles


    September 2017
  1. VERMA S, Weiskopf D, Gupta A, McDonald B, et al
    Erratum for Verma et al., "Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection".
    J Virol. 2017;91.
    PubMed     Text format    


    August 2017
  2. HAN Q, Williams WB, Saunders KO, Seaton KE, et al
    HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces Gp41 Antibody Immunodominance in Rhesus Macaques.
    J Virol. 2017 Aug 9. pii: JVI.00923-17. doi: 10.1128/JVI.00923.
    PubMed     Text format     Abstract available


  3. PIERCE BG, Boucher EN, Piepenbrink KH, Ejemel M, et al
    Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope.
    J Virol. 2017 Aug 9. pii: JVI.01032-17. doi: 10.1128/JVI.01032.
    PubMed     Text format     Abstract available


  4. GARG H, Sedano M, Plata G, Punke EB, et al
    Development of Virus like Particle Vaccine and Reporter Assay for Zika Virus.
    J Virol. 2017 Aug 9. pii: JVI.00834-17. doi: 10.1128/JVI.00834.
    PubMed     Text format     Abstract available


  5. WANG Q, Yan J, Gao GF
    Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design.
    J Virol. 2017 Aug 2. pii: JVI.01049-17. doi: 10.1128/JVI.01049.
    PubMed     Text format     Abstract available


  6. KAMAL RP, Blanchfield K, Belser JA, Music N, et al
    Inactivated H7 influenza virus vaccines protect mice despite low levels of neutralizing antibodies.
    J Virol. 2017 Aug 2. pii: JVI.01202-17. doi: 10.1128/JVI.01202.
    PubMed     Text format     Abstract available


  7. BRITT WJ
    Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    July 2017
  8. SENKEVICH TG, Katsafanas G, Weisberg A, Olano LR, et al
    Identification of Vaccinia Virus Replisome and Transcriptome Proteins by iPOND Coupled with Mass Spectrometry.
    J Virol. 2017 Jul 26. pii: JVI.01015-17. doi: 10.1128/JVI.01015.
    PubMed     Text format     Abstract available


  9. PHAN SI, Adam CM, Chen Z, Citron M, et al
    The genetic stability of PIV5-vectored RSV vaccine candidates after in vitro and in vivo passage.
    J Virol. 2017 Jul 26. pii: JVI.00559-17. doi: 10.1128/JVI.00559.
    PubMed     Text format     Abstract available


  10. KUMAR J, Yadav VN, Phulera S, Kamble A, et al
    Species specificity of vaccinia virus complement control protein towards bovine classical pathway is governed primarily by direct interaction of its acidic residues with factor I.
    J Virol. 2017 Jul 19. pii: JVI.00668-17. doi: 10.1128/JVI.00668.
    PubMed     Text format     Abstract available


  11. WANG K, Tomaras GD, Jegaskanda S, Moody MA, et al
    Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate ADCC, and Protect Mice from Ocular Challenge with HSV-1
    J Virol. 2017 Jul 12. pii: JVI.00411-17. doi: 10.1128/JVI.00411.
    PubMed     Text format     Abstract available


  12. BOGERS WMJM, Barnett SW, Oostermeijer H, Nieuwenhuis IG, et al
    Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    J Virol. 2017 Jul 12. pii: JVI.00811-17. doi: 10.1128/JVI.00811.
    PubMed     Text format     Abstract available


  13. BAUER A, Podola L, Mann P, Missanga M, et al
    Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA prime - Modified Vaccinia Ankara (MVA) boost HIV-1 vaccine regimen.
    J Virol. 2017 Jul 12. pii: JVI.00730-17. doi: 10.1128/JVI.00730.
    PubMed     Text format     Abstract available


    June 2017
  14. KASANI SK, Cheng HY, Yeh KE, Chang SJ, et al
    Differential innate immune signaling in macrophages by wild type vaccinia mature virus and a mutant virus deleting A26 protein.
    J Virol. 2017 Jun 28. pii: JVI.00767-17. doi: 10.1128/JVI.00767.
    PubMed     Text format     Abstract available


  15. LENNEMANN NJ, Herbert AS, Brouillette R, Rhein B, et al
    Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice.
    J Virol. 2017 Jun 14. pii: JVI.00479-17. doi: 10.1128/JVI.00479.
    PubMed     Text format     Abstract available


  16. BISCHOF GF, Magnani DM, Ricciardi M, Shin YC, et al
    Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector Against Dengue Virus in Rhesus Monkeys.
    J Virol. 2017 Jun 7. pii: JVI.00525-17. doi: 10.1128/JVI.00525.
    PubMed     Text format     Abstract available


  17. BALE S, Goebrecht G, Stano A, Wilson R, et al
    Covalent linkage of HIV-1 trimers to synthetic liposomes elicits improved B cell and antibody responses.
    J Virol. 2017 Jun 7. pii: JVI.00443-17. doi: 10.1128/JVI.00443.
    PubMed     Text format     Abstract available


  18. MUNOZ-ALIA MA, Muller CP, Russell SJ
    Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  19. WANG D, Phan S, DiStefano DJ, Citron MP, et al
    A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    May 2017
  20. LEE SY, Lee YJ, Kim RH, Park JN, et al
    Rapid Engineering for Vaccine and Challenge Viruses against Foot-and-Mouth Disease.
    J Virol. 2017 May 31. pii: JVI.00155-17. doi: 10.1128/JVI.00155.
    PubMed     Text format     Abstract available


  21. LIANG B, Ngwuta JO, Surman S, Kabatova B, et al
    Improved prefusion stability, optimized codon-usage, and augmented virion packaging enhance the immunogenicity of respiratory syncytial virus (RSV) fusion protein in a vectored vaccine candidate.
    J Virol. 2017 May 24. pii: JVI.00189-17. doi: 10.1128/JVI.00189.
    PubMed     Text format     Abstract available


  22. RINGE RP, Ozorowski G, Rantalainen K, Struwe WB, et al
    Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP trimers.
    J Virol. 2017 May 24. pii: JVI.00677-17. doi: 10.1128/JVI.00677.
    PubMed     Text format     Abstract available


  23. JIANG RT, Wang JW, Peng S, Huang TC, et al
    Spontaneous and vaccine-induced clearance of Mus musculus Papillomavirus type 1 (MmuPV1/MusPV1) infection.
    J Virol. 2017 May 17. pii: JVI.00699-17. doi: 10.1128/JVI.00699.
    PubMed     Text format     Abstract available


  24. OLSON AT, Rico AB, Wang Z, Delhon G, et al
    Deletion of the Vaccinia B1 Kinase Reveals Essential Functions of this Enzyme Complemented Partly by the Homologous Cellular Kinase VRK2.
    J Virol. 2017 May 17. pii: JVI.00635-17. doi: 10.1128/JVI.00635.
    PubMed     Text format     Abstract available


  25. SCOTT KA, Kotecha A, Seago J, Ren J, et al
    SAT2 Foot-and-Mouth Disease Virus Structurally Modified for Increased Thermostability.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  26. ZHANG L, Li H, Hai Y, Yin W, et al
    CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  27. BOONNAK K, Matsuoka Y, Wang W, Suguitan AL Jr, et al
    Development of clade-specific and broadly reactive live attenuated influenza virus vaccines against rapidly evolving H5 subtype viruses.
    J Virol. 2017 May 10. pii: JVI.00547-17. doi: 10.1128/JVI.00547.
    PubMed     Text format     Abstract available


  28. HYUN SI, Weisberg A, Moss B
    Deletion of the Vaccinia Virus I2 Protein Interrupts Virion Morphogenesis Leading to Retention of the Scaffold Protein and Mislocalization of Membrane-Associated Entry Proteins.
    J Virol. 2017 May 10. pii: JVI.00558-17. doi: 10.1128/JVI.00558.
    PubMed     Text format     Abstract available


  29. CRUZ AGB, Han A, Roy EJ, Guzman AB, et al
    Deletion of the K1L gene results in a vaccinia virus that is less pathogenic due to muted innate immune responses, yet still elicits protective immunity.
    J Virol. 2017 May 10. pii: JVI.00542-17. doi: 10.1128/JVI.00542.
    PubMed     Text format     Abstract available


    April 2017
  30. FILSKOV J, Mikkelsen M, Hansen PR, Christensen JP, et al
    Broadening CD4+ and CD8+ T cell responses against hepatitis C virus by vaccination with NS3 overlapping peptide panels in cross-priming liposomes.
    J Virol. 2017 Apr 26. pii: JVI.00130-17. doi: 10.1128/JVI.00130.
    PubMed     Text format     Abstract available


  31. ZHANG Z, Dong Z, Li J, Carr MJ, et al
    Protective efficacy of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection.
    J Virol. 2017 Apr 19. pii: JVI.00333-17. doi: 10.1128/JVI.00333.
    PubMed     Text format     Abstract available


  32. DI PILATO M, Mejias-Perez E, Sorzano COS, Esteban M, et al
    Distinct roles of vaccinia virus NF-kB inhibitor proteins A52, B15 and K7 in the immune response.
    J Virol. 2017 Apr 19. pii: JVI.00575-17. doi: 10.1128/JVI.00575.
    PubMed     Text format     Abstract available


  33. LIU SA, Stanfield BA, Chouljenko VN, Naidu S, et al
    Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus Type-1(HSV-1) Vaccine Strain VC2 Expressing the Equine Herpesvirus-1 (EHV-1) Glycoprotein D (gD) Generates Anti-EHV-1 Immune Responses in Mice.
    J Virol. 2017 Apr 12. pii: JVI.02445-16. doi: 10.1128/JVI.02445.
    PubMed     Text format     Abstract available


  34. SANTOS JJ, Finch C, Sutton T, Obadan A, et al
    Development of an alternative modified live Influenza B virus vaccine.
    J Virol. 2017 Apr 5. pii: JVI.00056-17. doi: 10.1128/JVI.00056.
    PubMed     Text format     Abstract available


    March 2017
  35. ERMLER M, Kirkpatrick E, Sun W, Hai R, et al
    Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model.
    J Virol. 2017 Mar 29. pii: JVI.00286-17. doi: 10.1128/JVI.00286.
    PubMed     Text format     Abstract available


  36. SCHWENEKER M, Laimbacher AS, Zimmer G, Wagner S, et al
    Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles.
    J Virol. 2017 Mar 22. pii: JVI.00343-17. doi: 10.1128/JVI.00343.
    PubMed     Text format     Abstract available


  37. KWON HI, Kim YI, Park SJ, Song MS, et al
    Evaluation of the immune responses to and cross-protective efficacy of Eurasian H7 avian influenza viruses.
    J Virol. 2017 Mar 22. pii: JVI.02259-16. doi: 10.1128/JVI.02259.
    PubMed     Text format     Abstract available


  38. LUO H, Winkelmann E, Xie G, Fang R, et al
    MAVS Is Essential for Primary CD4+ T Cell Immunity but Not for Recall T Cell Responses following an Attenuated West Nile Virus Infection.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  39. BOYOGLU-BARNUM S, Todd SO, Meng J, Barnum TR, et al
    Mutating the CX3C motif in the G protein should make a live respiratory syncytial virus vaccine safer and more effective.
    J Virol. 2017 Mar 8. pii: JVI.02059-16. doi: 10.1128/JVI.02059.
    PubMed     Text format     Abstract available


  40. MENG X, Rose L, Han Y, Deng J, et al
    Vaccinia virus A6 is a two-domain protein requiring a cognate N-terminal domain for full viral membrane assembly activity.
    J Virol. 2017 Mar 8. pii: JVI.02405-16. doi: 10.1128/JVI.02405.
    PubMed     Text format     Abstract available


  41. CHUANG GY, Geng H, Pancera M, Xu K, et al
    Structure-Based Design of a Soluble Prefusion-Closed HIV-1-Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
    J Virol. 2017 Mar 8. pii: JVI.02268-16. doi: 10.1128/JVI.02268.
    PubMed     Text format     Abstract available


  42. WIEGAND MA, Gori-Savellini G, Gandolfo C, Papa G, et al
    Respiratory syncytial virus (RSV) vaccine vectored by a stable chimeric and replication-deficient Sendai virus protects mice without inducing enhanced disease.
    J Virol. 2017 Mar 1. pii: JVI.02298-16. doi: 10.1128/JVI.02298.
    PubMed     Text format     Abstract available


  43. ZHANG Z, Dong Z, Wei Q, Carr MJ, et al
    A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.
    J Virol. 2017 Mar 1. pii: JVI.02450-16. doi: 10.1128/JVI.02450.
    PubMed     Text format     Abstract available


  44. LINGEMANN M, Liu X, Surman S, Liang B, et al
    Attenuated Human Parainfluenza Virus type 1 expressing Ebola Virus Glycoprotein GP Administered Intranasally is Immunogenic in African Green Monkeys.
    J Virol. 2017 Mar 1. pii: JVI.02469-16. doi: 10.1128/JVI.02469.
    PubMed     Text format     Abstract available


    February 2017
  45. GRANT CF, Carr BV, Kotecha A, van den Born E, et al
    The B cell response to foot-and-mouth disease virus in cattle following sequential vaccination with multiple serotypes.
    J Virol. 2017 Feb 22. pii: JVI.02157-16. doi: 10.1128/JVI.02157.
    PubMed     Text format     Abstract available


  46. HENSEL MT, Marshall JD, Dorwart MR, Heeke DS, et al
    Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reserv
    J Virol. 2017 Feb 22. pii: JVI.02257-16. doi: 10.1128/JVI.02257.
    PubMed     Text format     Abstract available


  47. MARTINEZ DR, Vandergrift N, Douglas AO, McGuire E, et al
    Maternal binding and neutralizing IgG responses targeting the C terminal region of the V3 loop are predictive of reduced peripartum HIV-1 transmission risk.
    J Virol. 2017 Feb 15. pii: JVI.02422-16. doi: 10.1128/JVI.02422.
    PubMed     Text format     Abstract available


  48. GO EP, Ding H, Zhang S, Ringe RP, et al
    A glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven Env trimers.
    J Virol. 2017 Feb 15. pii: JVI.02428-16. doi: 10.1128/JVI.02428.
    PubMed     Text format     Abstract available


  49. ZURAWSKI G, Shen X, Zurawski S, Tomaras GD, et al
    Superiority in Rhesus Macaques of Targeting HIV-1 Env Gp140 to CD40 Versus LOX-1 in Combination with Replication Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    J Virol. 2017 Feb 15. pii: JVI.01596-16. doi: 10.1128/JVI.01596.
    PubMed     Text format     Abstract available


  50. BRAUN C, Thurmer A, Daniel R, Schultz AK, et al
    Genetic Variability of Myxoma Virus Genomes.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  51. GARCIA-ARRIAZA J, Perdiguero B, Heeney JL, Seaman MS, et al
    HIV/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived VLPs or lacking the viral molecule B19 that inhibits type I interferon activate relevant HIV-1-specific B and T cell i
    J Virol. 2017 Feb 8. pii: JVI.02182-16. doi: 10.1128/JVI.02182.
    PubMed     Text format     Abstract available


  52. JIANG W, Wang S, Chen H, Ren H, et al
    A bivalent heterologous DNA-virus-like particles prime-boost vaccine elicits broad protection against both groups 1 and 2 influenza A viruses.
    J Virol. 2017 Feb 8. pii: JVI.02052-16. doi: 10.1128/JVI.02052.
    PubMed     Text format     Abstract available


  53. NASAR F, Matassov D, Seymour RL, Latham T, et al
    Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single dose protection against lethal alphavirus challenge.
    J Virol. 2017 Feb 1. pii: JVI.01729-16. doi: 10.1128/JVI.01729.
    PubMed     Text format     Abstract available


  54. HALEY SL, Tzvetkov EP, Meuwissen S, Plummer JR, et al
    Targeting Vaccine-induced Extrafollicular Pathway of B cell Differentiation Improves Rabies Post-exposure Prophylaxis.
    J Virol. 2017 Feb 1. pii: JVI.02435-16. doi: 10.1128/JVI.02435.
    PubMed     Text format     Abstract available


  55. SCHNEIDER-OHRUM K, Cayatte C, Snell Bennett A, Manohar Rajani G, et al
    Immunization with low doses of recombinant post-fusion or pre-fusion RSV F primes for vaccine-enhanced disease in the cotton rat model independent of the presence of a Th1-biasing (GLA-SE) or Th2-biasing (Alum) adjuvant.
    J Virol. 2017 Feb 1. pii: JVI.02180-16. doi: 10.1128/JVI.02180.
    PubMed     Text format     Abstract available


  56. BUDASZEWSKI RD, Hudacek A, Sawatsky B, Kramer B, et al
    Inactivated Recombinant Rabies Viruses Displaying the Canine Distemper Virus Glycoproteins Induce Protective Immunity Against Both Pathogens.
    J Virol. 2017 Feb 1. pii: JVI.02077-16. doi: 10.1128/JVI.02077.
    PubMed     Text format     Abstract available


    January 2017
  57. ROYER DJ, Carr MM, Chucair-Elliott AJ, Halford WP, et al
    Impact of type 1 interferon on the safety and immunogenicity of an experimental live-attenuated herpes simplex virus type 1 vaccine in mice.
    J Virol. 2017 Jan 25. pii: JVI.02342-16. doi: 10.1128/JVI.02342.
    PubMed     Text format     Abstract available


  58. TANG X, Yang Y, Xia X, Zhang C, et al
    Recombinant adenoviruses displaying matrix 2 ectodomain epitopes (M2e) on their fiber proteins as universal influenza vaccines.
    J Virol. 2017 Jan 18. pii: JVI.02462-16. doi: 10.1128/JVI.02462.
    PubMed     Text format     Abstract available


  59. LI Y, Zhou M, Luo Z, Zhang Y, et al
    Overexpression of IL-7 extends the humoral immune response induced by rabies vaccination.
    J Virol. 2017 Jan 18. pii: JVI.02324-16. doi: 10.1128/JVI.02324.
    PubMed     Text format     Abstract available


  60. PREVOST J, Zoubchenok D, Richard J, Veillette M, et al
    Influence of the Envelope Gp120 Phe 43 Cavity on HIV-1 Sensitivity to ADCC Responses.
    J Virol. 2017 Jan 18. pii: JVI.02452-16. doi: 10.1128/JVI.02452.
    PubMed     Text format     Abstract available


  61. KIM SM, Kim YI, Park SJ, Kim EH, et al
    Vaccine efficacy of an inactivated, chimeric HA H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy.
    J Virol. 2017 Jan 11. pii: JVI.01693-16. doi: 10.1128/JVI.01693.
    PubMed     Text format     Abstract available


  62. VAN DEN HOECKE S, Ehrhardt K, Kolpe A, El Bakkouri K, et al
    Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies.
    J Virol. 2017 Jan 11. pii: JVI.02500-16. doi: 10.1128/JVI.02500.
    PubMed     Text format     Abstract available


  63. HA S, Li F, Troutman MC, Freed DC, et al
    Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targets Viral gH/gL/pUL128-131 Pentameric Complex.
    J Virol. 2017 Jan 11. pii: JVI.02033-16. doi: 10.1128/JVI.02033.
    PubMed     Text format     Abstract available


  64. VAN DEN POL AN, Mao G, Chattopadhyay A, Rose JK, et al
    Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
    J Virol. 2017 Jan 11. pii: JVI.02154-16. doi: 10.1128/JVI.02154.
    PubMed     Text format     Abstract available


  65. NAITO T, Mori K, Ushirogawa H, Takizawa N, et al
    Generation of a genetically stable high-fidelity influenza vaccine strain.
    J Virol. 2017 Jan 4. pii: JVI.01073-16. doi: 10.1128/JVI.01073.
    PubMed     Text format     Abstract available


  66. O'DONNELL V, Risatti GR, Holinka LG, Krug PW, et al
    Simultaneous Deletion of the 9GL and UK Genes from the African Swine Fever Virus Georgia 2007 Isolate Offers Increased Safety and Protection against Homologous Challenge.
    J Virol. 2016;91.
    PubMed     Text format     Abstract available


  67. TAI W, Wang Y, Fett CA, Zhao G, et al
    Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    J Virol. 2016;91.
    PubMed     Text format     Abstract available


  68. FIGUEIRA TN, Palermo LM, Veiga AS, Huey D, et al
    In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.
    J Virol. 2016;91.
    PubMed     Text format     Abstract available


    December 2016
  69. NIVARTHI UK, Kose N, Sapparapu G, Widman D, et al
    Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination.
    J Virol. 2016 Dec 28. pii: JVI.02041-16. doi: 10.1128/JVI.02041.
    PubMed     Text format     Abstract available


  70. DAI A, Cao S, Dhungel P, Luan Y, et al
    Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation mRNAs During Vaccinia Virus-induced Host Shutoff.
    J Virol. 2016 Dec 21. pii: JVI.01858-16. doi: 10.1128/JVI.01858.
    PubMed     Text format     Abstract available


  71. LEE J, Hashimoto M, Im SJ, Araki K, et al
    Adenovirus serotype 5 vaccination results in suboptimal CD4 T helper 1 responses in mice.
    J Virol. 2016 Dec 21. pii: JVI.01132-16. doi: 10.1128/JVI.01132.
    PubMed     Text format     Abstract available


  72. EDUARDO-CORREIA B, Martinez-Romero C, Garcia-Sastre A, Guerra S, et al
    Correction for Eduardo-Correia et al., ISG15 Is Counteracted by Vaccinia Virus E3 Protein and Controls the Proinflammatory Response against Viral Infection.
    J Virol. 2016;90:11280.
    PubMed     Text format    


  73. ANGELO MA, Grifoni A, O'Rourke PH, Sidney J, et al
    Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity.
    J Virol. 2016 Dec 14. pii: JVI.02147.
    PubMed     Text format     Abstract available


  74. NOGALES A, Rodriguez L, Chauche C, Huang K, et al
    A temperature sensitive live-attenuated canine influenza virus H3N8 vaccine.
    J Virol. 2016 Dec 7. pii: JVI.02211.
    PubMed     Text format     Abstract available


  75. CONE KR, Kronenberg ZN, Yandell M, Elde NC, et al
    Emergence of a viral RNA polymerase variant during gene copy number amplification promotes rapid evolution of vaccinia virus.
    J Virol. 2016 Dec 7. pii: JVI.01428.
    PubMed     Text format     Abstract available


  76. SHAW JM, Miller-Novak LK, Mohanram V, McKinnon K, et al
    Influence of Plasma Cell Niche Factors on the Recruitment and Maintenance of IRF4hi Plasma Cells and Plasmablasts in Vaccinated, SIV-Infected Rhesus Macaques with Low and High Viremia.
    J Virol. 2016 Dec 7. pii: JVI.01727.
    PubMed     Text format     Abstract available


  77. KASTURI SP, Kozlowski PA, Nakaya HI, Burger MC, et al
    Adjuvanting an SIV vaccine with TLR ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5alpha restrictive macaques.
    J Virol. 2016 Dec 7. pii: JVI.01844.
    PubMed     Text format     Abstract available


    November 2016
  78. WANG Z, Li M, Zhou M, Zhang Y, et al
    A Novel Rabies Vaccine Expressing CXCL13 Enhances Humoral Immunity by Recruiting both T Follicular Helper and Germinal Center B Cells.
    J Virol. 2016 Nov 16. pii: JVI.01956.
    PubMed     Text format     Abstract available


  79. WIRBLICH C, Coleman CM, Kurup D, Abraham TS, et al
    One-Health: A Safe, Efficient Dual-use Vaccine for Humans and Animals against MERS-CoV and Rabies Virus.
    J Virol. 2016 Nov 2. pii: JVI.02040.
    PubMed     Text format     Abstract available


  80. CROSBY CM, Matchett WE, Anguiano-Zarate SS, Parks CA, et al
    Replicating Single-cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.
    J Virol. 2016 Nov 2. pii: JVI.00720.
    PubMed     Text format     Abstract available


    October 2016
  81. CELMA CC, Stewart M, Wernike K, Eschbaumer M, et al
    Replication-deficient particles: New insights into the next generation of bluetongue virus vaccines.
    J Virol. 2016 Oct 26. pii: JVI.01892.
    PubMed     Text format     Abstract available


  82. LOGAN M, Law J, Wong JA, Hockman D, et al
    Native folding of a recombinant gpE1/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG.
    J Virol. 2016 Oct 19. pii: JVI.01552.
    PubMed     Text format     Abstract available


  83. JIANG X, Totrov M, Li W, Sampson JM, et al
    Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    J Virol. 2016 Oct 5. pii: JVI.01409.
    PubMed     Text format     Abstract available


    September 2016
  84. ROUXEL RN, Tafalla C, Merour E, Leal E, et al
    Attenuated Infectious Hematopoietic Necrosis Virus (IHNV) with rearranged gene order as potential vaccine.
    J Virol. 2016 Sep 28. pii: JVI.01024.
    PubMed     Text format     Abstract available


  85. LI D, von Schaewen M, Wang X, Tao W, et al
    Altered glycosylation patterns increase immunogenicity of a subunit HCV vaccine inducing neutralizing antibodies which confer protection in mice.
    J Virol. 2016 Sep 14. pii: JVI.01462.
    PubMed     Text format     Abstract available


  86. ZOLLA-PAZNER S, Powell R, Yahyaei S, Williams C, et al
    RATIONALLY-DESIGNED VACCINES TARGETING THE V2 REGION OF HIV-1 gp120 INDUCE A FOCUSED, CROSS CLADE-REACTIVE, BIOLOGICALLY FUNCTIONAL ANTIBODY RESPONSE.
    J Virol. 2016 Sep 14. pii: JVI.01403.
    PubMed     Text format     Abstract available


  87. COSTA M, Pollara J, Edwards RW, Seaman M, et al
    Fc receptor mediated activities by Env-specific human mAbs generated from volunteers receiving the DNA prime-protein boost HIV vaccine DP6-001.
    J Virol. 2016 Sep 14. pii: JVI.01458.
    PubMed     Text format     Abstract available


    August 2016
  88. HARRISON K, Haga IR, Pechenick Jowers T, Jasim S, et al
    Vaccinia virus uses retromer-independent cellular retrograde transport pathways to facilitate the wrapping of intracellular mature virions during viral morphogenesis.
    J Virol. 2016 Aug 31. pii: JVI.01464.
    PubMed     Text format     Abstract available


  89. SCHNEIDER-OHRUM K, Cayatte C, Liu Y, Wang Z, et al
    Production of cytomegalovirus dense bodies by scalable bioprocess methods maintains immunogenicity and improves neutralizing antibody titers.
    J Virol. 2016 Aug 31. pii: JVI.00463.
    PubMed     Text format     Abstract available


  90. WIBMER CK, Gorman J, Anthony CS, Mkhize NN, et al
    Structure of an N276-dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole adjacent to the CD4 Binding Site.
    J Virol. 2016 Aug 31. pii: JVI.01357.
    PubMed     Text format     Abstract available


  91. ALTENBURG AF, van de Sandt CE, van Trierum SE, De Gruyter HL, et al
    Increased Protein Degradation Improves Influenza Virus Nucleoprotein-specific CD8+ T cell Activation in vitro but not in C57BL/6 mice.
    J Virol. 2016 Aug 31. pii: JVI.01633.
    PubMed     Text format     Abstract available


  92. LIANG B, Ngwuta JO, Herbert R, Swerczek J, et al
    Packaging and prefusion stabilization separately and additively increase the quantity and quality of RSV-neutralizing antibodies induced by respiratory syncytial virus (RSV) fusion protein expressed by a parainfluenza vector.
    J Virol. 2016 Aug 31. pii: JVI.01196.
    PubMed     Text format     Abstract available


  93. NGO T, Mirzakhanyan Y, Moussatche N, Gershon PD, et al
    Protein primary structure of the Vaccinia virion at increased resolution.
    J Virol. 2016 Aug 24. pii: JVI.01042.
    PubMed     Text format     Abstract available


  94. LIU L, Zeng X, Chen P, Deng G, et al
    Characterization of Clade 7.2 H5 Avian Influenza Viruses That Continue to Circulate in Chickens in China.
    J Virol. 2016 Aug 24. pii: JVI.00855.
    PubMed     Text format     Abstract available


  95. AYALA VI, Trivett MT, Barsov EV, Jain S, et al
    Adoptive Transfer of Engineered Rhesus SIV-Specific CD8+ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques.
    J Virol. 2016 Aug 24. pii: JVI.01522.
    PubMed     Text format     Abstract available


  96. VERKERKE HP, Williams JA, Guttman M, Simonich CA, et al
    Epitope-independent purification of native-like envelope trimers from diverse HIV-1 isolates.
    J Virol. 2016 Aug 10. pii: JVI.01351.
    PubMed     Text format     Abstract available


  97. TALKER SC, Stadler M, Koinig HC, Mair KH, et al
    Influenza A virus infection in pigs attracts multifunctional and cross-reactive T cells to the lung.
    J Virol. 2016 Aug 10. pii: JVI.01211.
    PubMed     Text format     Abstract available


  98. LIANG Y, Guttman M, Williams JA, Verkerke H, et al
    Changes in structure and antigenicity of HIV-1 Env trimers resulting from removal of a conserved CD4 binding site-proximal glycan.
    J Virol. 2016 Aug 3. pii: JVI.01116.
    PubMed     Text format     Abstract available


    July 2016
  99. IYER SS, Gangadhara S, Victor B, Shen X, et al
    Virus-like particles displaying trimeric SIV envelope gp160 enhance the breadth of DNA/MVA SIV vaccine induced antibody responses in rhesus macaques.
    J Virol. 2016 Jul 27. pii: JVI.01163.
    PubMed     Text format     Abstract available


  100. SIVAN G, Weisberg AS, Americo JL, Moss B, et al
    Retrograde Transport from Early Endosomes to the Trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virions.
    J Virol. 2016 Jul 27. pii: JVI.01114.
    PubMed     Text format     Abstract available


  101. LIU WC, Jan JT, Huang YJ, Chen TH, et al
    Unmasking stem-specific neutralizing epitopes by abolishing N-linked glycosylation sites of influenza hemagglutinin proteins for vaccine design.
    J Virol. 2016 Jul 20. pii: JVI.00880.
    PubMed     Text format     Abstract available


  102. ZHOU B, Meliopoulos VA, Wang W, Lin X, et al
    Reversion of Cold-adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.
    J Virol. 2016 Jul 20. pii: JVI.00163.
    PubMed     Text format     Abstract available


  103. GACH JS, Venzon D, Vaccari M, Keele BF, et al
    The relationship between vaccine-induced antibody capture of infectious virus and infection outcomes following low-dose, repeated rectal challenge with SIVmac251.
    J Virol. 2016 Jul 20. pii: JVI.00812.
    PubMed     Text format     Abstract available


  104. DEPLEDGE DP, Yamanishi K, Gomi Y, Gershon A, et al
    Deep-sequencing of distinct preparations of the live-attenuated VZV vaccine reveals a conserved core of attenuating SNPs.
    J Virol. 2016 Jul 20. pii: JVI.00998.
    PubMed     Text format     Abstract available


  105. TOWNSLEY S, Mohamed Z, Guo W, McKenna J, et al
    Induction of heterologous Tier 2 HIV-1 neutralizing and cross-reactive V1/V2-specific antibodies in rabbits by prime-boost immunization.
    J Virol. 2016 Jul 20. pii: JVI.00853.
    PubMed     Text format     Abstract available


    June 2016
  106. CHOI KY, Root M, McGregor A
    A Novel Non-Replication Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.
    J Virol. 2016 Jun 22. pii: JVI.00283.
    PubMed     Text format     Abstract available


  107. LIU R, Moss B
    Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR/Cas9 Knock-Out Cell Lines and Vaccinia Virus Mutants.
    J Virol. 2016 Jun 22. pii: JVI.00869.
    PubMed     Text format     Abstract available


  108. ROSTAD CA, Stobart CC, Gilbert BE, Pickles RJ, et al
    A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats.
    J Virol. 2016 Jun 8. pii: JVI.00012.
    PubMed     Text format     Abstract available


  109. LULLA V, Lulla A, Wernike K, Aebischer A, et al
    Assembly of replication-incompetent African horse sickness virus particles: rational design of vaccines for all serotypes.
    J Virol. 2016 Jun 8. pii: JVI.00548.
    PubMed     Text format     Abstract available


  110. JENSEN K, Nabi R, Van Rompay KK, Robichaux S, et al
    Vaccine-elicited mucosal and systemic antibody responses are associated with reduced simian immunodeficiency viremia in infant rhesus macaques.
    J Virol. 2016 Jun 1. pii: JVI.00481.
    PubMed     Text format     Abstract available


  111. CASTRO I, Giret TM, Magnani DM, Maxwell HS, et al
    Cellular Immune Responses against Simian T-Lymphotropic Virus Type 1 Target Tax in Infected Baboons.
    J Virol. 2016;90:5280-91.
    PubMed     Text format     Abstract available


    May 2016
  112. KO EJ, Lee YT, Kim KH, Jung YJ, et al
    MF59 adjuvant effects on inducing isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells.
    J Virol. 2016 May 25. pii: JVI.00339.
    PubMed     Text format     Abstract available


  113. LEE YT, Ko EJ, Lee Y, Lee YN, et al
    CD47 plays a role as a negative regulator in inducing protective immune responses to vaccination against influenza virus.
    J Virol. 2016 May 18. pii: JVI.00605.
    PubMed     Text format     Abstract available


  114. KAMLANGDEE A, Kingstad-Bakke B, Osorio JE
    Mosaic H5 hemagglutinin provides broad humoral and cellular immune responses against influenza viruses.
    J Virol. 2016 May 18. pii: JVI.00730.
    PubMed     Text format     Abstract available


  115. LARSEN IV, Clausius H, Kolb AW, Brandt CR, et al
    Both CD8+ and CD4+ T-Cells Contribute to Corneal Clouding and Viral Clearance Following Vaccinia Virus Infection in C57BL/6 Mice.
    J Virol. 2016 May 11. pii: JVI.00570.
    PubMed     Text format     Abstract available


    April 2016
  116. TAYLOR A, Melton JV, Herrero LJ, Thaa B, et al
    Effects of an In-Frame Deletion of the 6k Gene Locus from the Genome of Ross River Virus.
    J Virol. 2016;90:4150-9.
    PubMed     Text format     Abstract available


    March 2016
  117. LAZEAR HM, Diamond MS
    Zika Virus: New Clinical Syndromes and its Emergence in the Western Hemisphere.
    J Virol. 2016 Mar 9. pii: JVI.00252.
    PubMed     Text format     Abstract available


  118. NELSON CS, Pollara J, Kunz EL, Jeffries TL Jr, et al
    Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces Robust IgA-Isotype B Cell Response in Breast Milk.
    J Virol. 2016 Mar 2. pii: JVI.00335.
    PubMed     Text format     Abstract available


  119. IWASAKI M, Cubitt B, Sullivan BM, de la Torre JC, et al
    The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
    J Virol. 2016;90:3187-97.
    PubMed     Text format     Abstract available


    February 2016
  120. DIAZ-SAN SEGUNDO F, Medina GN, Ramirez-Medina E, Velazquez-Salinas L, et al
    Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes Attenuation In Vivo while Inducing a Strong Neutralizing Antibody Response.
    J Virol. 2015;90:1298-310.
    PubMed     Text format     Abstract available


  121. YEN LC, Liao JT, Lee HJ, Chou WY, et al
    The C Terminus of the Core beta-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.
    J Virol. 2015;90:1178-89.
    PubMed     Text format     Abstract available


    January 2016
  122. SEN N, Arvin AM
    Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells.
    J Virol. 2016;90:3284-7.
    PubMed     Text format     Abstract available


  123. CHEN CJ, Ermler ME, Tan GS, Krammer F, et al
    Influenza A viruses expressing intra- or inter-group chimeric hemagglutinins.
    J Virol. 2016 Jan 13. pii: JVI.03060.
    PubMed     Text format     Abstract available


  124. PATIL S, Kumar R, Deshpande S, Samal S, et al
    Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in V1 Loop.
    J Virol. 2016 Jan 13. pii: JVI.03090.
    PubMed     Text format     Abstract available


  125. DINIS JM, Florek NW, Fatola OO, Moncla LH, et al
    Deep sequencing reveals potential antigenic variants at low frequency in influenza A-infected humans.
    J Virol. 2016 Jan 6. pii: JVI.03248.
    PubMed     Text format     Abstract available


    December 2015
  126. CHENG C, Pancera M, Bossert A, Schmidt SD, et al
    Immunogenicity of a Prefusion HIV-1-Envelope Trimer in Complex with a Quaternary-Specific Antibody.
    J Virol. 2015 Dec 30. pii: JVI.02380.
    PubMed     Text format     Abstract available


  127. NACHBAGAUER R, Miller MS, Hai R, Ryder AB, et al
    Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets.
    J Virol. 2015 Dec 30. pii: JVI.02481.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: